303 related articles for article (PubMed ID: 30756365)
1. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS).
Januszewski M; Issat T; Jakimiuk AA; Santor-Zaczynska M; Jakimiuk AJ
Ginekol Pol; 2019; 90(1):7-10. PubMed ID: 30756365
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
Pustotina O; Myers SH; Unfer V; Rasulova I
Gynecol Obstet Invest; 2024; 89(2):131-139. PubMed ID: 38295772
[TBL] [Abstract][Full Text] [Related]
3. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
Nordio M; Basciani S; Camajani E
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5512-5521. PubMed ID: 31298405
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study.
Kachhawa G; Senthil Kumar KV; Kulshrestha V; Khadgawat R; Mahey R; Bhatla N
Int J Gynaecol Obstet; 2022 Aug; 158(2):278-284. PubMed ID: 34624138
[TBL] [Abstract][Full Text] [Related]
5. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Nordio M; Proietti E
Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
[TBL] [Abstract][Full Text] [Related]
6. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Croze ML; Soulage CO
Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
[TBL] [Abstract][Full Text] [Related]
7. Reflections on inositol(s) for PCOS therapy: steps toward success.
Nestler JE; Unfer V
Gynecol Endocrinol; 2015 Jul; 31(7):501-5. PubMed ID: 26177098
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol.
Laganà AS; Barbaro L; Pizzo A
Arch Gynecol Obstet; 2015 May; 291(5):1181-6. PubMed ID: 25416201
[TBL] [Abstract][Full Text] [Related]
9. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Pizzo A; Laganà AS; Barbaro L
Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
[TBL] [Abstract][Full Text] [Related]
10. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome.
Genazzani AD; Lanzoni C; Ricchieri F; Jasonni VM
Gynecol Endocrinol; 2008 Mar; 24(3):139-44. PubMed ID: 18335328
[TBL] [Abstract][Full Text] [Related]
11. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women.
Benelli E; Del Ghianda S; Di Cosmo C; Tonacchera M
Int J Endocrinol; 2016; 2016():3204083. PubMed ID: 27493664
[TBL] [Abstract][Full Text] [Related]
12. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
Genazzani AD; Prati A; Marchini F; Petrillo T; Napolitano A; Simoncini T
Gynecol Endocrinol; 2019 Dec; 35(12):1088-1093. PubMed ID: 31304823
[TBL] [Abstract][Full Text] [Related]
13. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
Fruzzetti F; Capozzi A; Canu A; Lello S
Gynecol Endocrinol; 2019 Jun; 35(6):506-510. PubMed ID: 30612488
[TBL] [Abstract][Full Text] [Related]
14. Management of polycystic ovary syndrome among Indian women using myo-inositol and D-chiro-inositol.
Vyas L; Raiturker AP; Sud S; Goyyal P; Abhyankar M; Revankar S; Walia S
Bioinformation; 2022; 18(2):103-110. PubMed ID: 36420435
[TBL] [Abstract][Full Text] [Related]
15. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
Laganà AS; Garzon S; Casarin J; Franchi M; Ghezzi F
Trends Endocrinol Metab; 2018 Nov; 29(11):768-780. PubMed ID: 30270194
[TBL] [Abstract][Full Text] [Related]
16. Inositols in Polycystic Ovary Syndrome: An Overview on the Advances.
Facchinetti F; Unfer V; Dewailly D; Kamenov ZA; Diamanti-Kandarakis E; Laganà AS; Nestler JE; Soulage CO;
Trends Endocrinol Metab; 2020 Jun; 31(6):435-447. PubMed ID: 32396844
[TBL] [Abstract][Full Text] [Related]
17. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
Monastra G; Unfer V; Harrath AH; Bizzarri M
Gynecol Endocrinol; 2017 Jan; 33(1):1-9. PubMed ID: 27898267
[TBL] [Abstract][Full Text] [Related]
18. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
Genazzani AD; Prati A; Santagni S; Ricchieri F; Chierchia E; Rattighieri E; Campedelli A; Simoncini T; Artini PG
Gynecol Endocrinol; 2012 Dec; 28(12):969-73. PubMed ID: 22612517
[TBL] [Abstract][Full Text] [Related]
19. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature.
Regidor PA; Schindler AE; Lesoine B; Druckman R
Horm Mol Biol Clin Investig; 2018 Mar; 34(2):. PubMed ID: 29498933
[TBL] [Abstract][Full Text] [Related]
20. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
Genazzani AD; Santagni S; Rattighieri E; Chierchia E; Despini G; Marini G; Prati A; Simoncini T
Gynecol Endocrinol; 2014 Jun; 30(6):438-43. PubMed ID: 24601829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
